These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Meningococcal carriage: the dilemma of 4CMenB vaccine. Taha MK; Deghmane AE Lancet; 2014 Dec; 384(9960):2088-90. PubMed ID: 25145776 [No Abstract] [Full Text] [Related]
29. [Effects of rifampin on the carrier state of Neisseria meningitidis and drug-sensitivity test (author's transl)]. Zhonghua Yu Fang Yi Xue Za Zhi; 1981 Nov; 15(6):371-2. PubMed ID: 6806022 [No Abstract] [Full Text] [Related]
30. In brief: Meningococcal prophylaxis. Med Lett Drugs Ther; 2008 Apr; 50(1283):25. PubMed ID: 18391897 [No Abstract] [Full Text] [Related]
31. The effect of coumermycin A on the meningococcal carrier state. Devine LF; Johnson DP; Hagerman CR; Pierce WE; Rhode SL; Peckinpaugh RO Am J Med Sci; 1970 Sep; 260(3):165-70. PubMed ID: 4991431 [No Abstract] [Full Text] [Related]
32. [Evaluation of the sanative action of rifampicin on the meningococcal carrier state]. Deviatkina NP; Demina AA; Orlova EV; Timina VP; Petrova IS Antibiotiki; 1978 Sep; 23(9):794-7. PubMed ID: 100048 [TBL] [Abstract][Full Text] [Related]
33. [The prevalence of nasopharyngeal Neisseria meningitidis carriage, serogroup distribution, and antibiotic resistance among healthy children in Cankaya municipality schools of Ankara province]. Ercis S; Köseoğlu O; Salmanzadeh-Ahrabi S; Ercis M; Akin L; Hasçelik C Mikrobiyol Bul; 2005 Oct; 39(4):411-20. PubMed ID: 16544542 [TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Schwartz B; Al-Tobaiqi A; Al-Ruwais A; Fontaine RE; A'ashi J; Hightower AW; Broome CV; Music SI Lancet; 1988 Jun; 1(8597):1239-42. PubMed ID: 2897515 [TBL] [Abstract][Full Text] [Related]
35. [Are environmental studies useful in meningococcal infections?]. Berger U Munch Med Wochenschr; 1968 Mar; 110(12):714-7. PubMed ID: 4970727 [No Abstract] [Full Text] [Related]
37. Mutation of gonococci and meningococci in vitro to rifampin (rifampicin) resistance. Schneider H; Dobek AS; Artenstein MS Br J Vener Dis; 1972 Dec; 48(6):500-3. PubMed ID: 4631230 [No Abstract] [Full Text] [Related]
38. [Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. Carabias ML; Cervera LA; García-Navas BL; entelles ML Rev Esp Quimioter; 2001 Jun; 14(2):177-83. PubMed ID: 11704772 [TBL] [Abstract][Full Text] [Related]
39. Study of the in-vitro sensitivity of meningococci and its implications in prophylaxis. Yourassowsky E; Schoutens E; Vanderlinden MP Acta Clin Belg; 1973; 28(5):281-6. PubMed ID: 4204781 [No Abstract] [Full Text] [Related]
40. [The use of rifampicin in healthy carriers of "N. meningitidis" (author's transl)]. Delia S; Mauro A; Miceli MT Ann Sclavo; 1978; 20(5):675-80. PubMed ID: 111629 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]